Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
December 26th, 2008
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of new data from two ongoing clinical trials demonstrating that the company's novel drug candidate, voreloxin, shows promising safety and efficacy results both in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). These data were presented today at two poster sessions at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The presentations are highlighted below. Phase 2 Study of Voreloxin as Single Agent Therapy (REVEAL-1 Trial) Interim data from the REVEAL-1 (Response Evaluation of VorEloxin in AmL) single agent Phase 2...
Source: Health Business Week (2008-12-26)
|
